Abstract
An increasing array of drugs can induce vasculitis, a process which causes necrotizing inflammation of vessels and, in turn, tissue ischaemia and inflammation. While most cases will be mild, presenting with arthralgia, malaise and cutaneous leucocytoclastic vasculitis, some cases can be severe and cause major organ involvement, critical illness and rarely death. Clinicians therefore need to be vigilant for systemic disease involvement, stop the offending agent promptly and initiate immunomodulatory therapy when necessary. Novel cancer immunotherapeutic agents such as checkpoint inhibitors (CPIs) are associated with a growing spectrum of rheumatic side effects, including vasculitis. Collectively, these are termed immune related adverse events (irAEs). In this chapter, the drugs most frequently associated with drug-induced vasculitis are discussed, known pathogenic mechanisms are explored, and a clinical approach to diagnosis and management is outlined.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AAV:
-
ANCA associated vasculitis
- ANA:
-
Anti-nuclear antibody
- ANCA:
-
Anti neutrophil cytoplasmic antibody
- BAFF:
-
B-cell activating factor
- bDMARD:
-
Biologic disease modifying anti rheumatic drug
- BVAS:
-
Birmingham vasculitis activity score
- CPI:
-
Checkpoint inhibitor
- CTCAE:
-
Common Terminology Criteria for Adverse Events
- DIV:
-
Drug induced vasculitis
- DMARD:
-
Disease-modifying anti-rheumatic drug
- EULAR:
-
European league against rheumatism
- IBD:
-
Inflammatory bowel disease
- irAE:
-
Immune-related adverse event
- MPO:
-
Myeloperoxidase
- NE:
-
Neutrophil elastase
- NETs:
-
Neutrophil extracellular traps
- PR3:
-
Proteinase 3
- PTU:
-
Propylthiouracil
- RA:
-
Rheumatoid arthritis
- TNF:
-
Tumour necrosis factor
References
Abe K, Itoh M, Asahina A. Rituximab-induced vasculitis: does the immune complex of rituximab play a key role in developing paradoxical adverse events? J Dermatol. 2019;46:e311–2.
Alloo A, Khosravi H, Granter SR, Jadeja SM, Richardson PG, Castillo JJ, et al. Ixazomib-induced cutaneous necrotizing vasculitis. Support Care Cancer. 2018;26(7):2247–50.
An J, Garje R, Wanat KA, Leone JP. Dabigatran-related leukocytoclastic vasculitis. BMJ Case Rep. 2017;2017:bcr2016217423.
Bock VL, Friedlander M, Waring D, Kossard S, Wood GK. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. Australas J Dermatol. 2014;55(4):282–5.
Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol. 2012;198:773–83.
Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018;14:569–79.
Carmona-Rivera C, Purmalek MM, Moore E, Waldman M, Walter PJ, Garraffo HM, et al. A role for muscarinic receptors in neutrophil extracellular trap formation and levamisole-induced autoimmunity. JCI Insight. 2017;2(3):e89780.
Chaaya G, Jaller-Char J, Ghaffar E, Castiglioni A. Rivaroxaban-induced leukocytoclastic vasculitis: a challenging rash. Ann Allergy Asthma Immunol. 2016;116(6):577–8.
Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors—a systematic review. Clin Rheumatol. 2018;37:2579–84.
Dean R, Messer AM, Pickett M, Jahan-Tigh R. A case of leukocytoclastic vasculitis caused by novel anticoagulant rivaroxaban. Dermatol Online J. 2017;23(11):13030.
Digklia A, Tzika E, Voutsadakis IA. Cutaneous leukocytoclastic vasculitis associated with letrozole. J Oncol Pharm Pract. 2014;20(2):146–8.
Fekete GL, Fekete L. Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: a case report and review of the literature. Exp Ther Med. 2019;17(2):1128–31.
Hamada T, Miyake T, Otsuka M, Iwatsuki K. Warfarin-induced skin necrosis accompanied by aggravation of vasculitis in a patient with cutaneous arteritis. Int J Dermatol. 2017;56(7):779–81.
Hsu CY, Chen WS, Sung SH. Warfarin-induced leukocytoclastic vasculitis: a case report and review of literature. Intern Med. 2012;51:601–6.
Kamo H, Shinozaki E, Sugase T, Mizunuma N, Taniguchi S, Gotoh T, et al. Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report. J Med Case Rep. 2019;13(1):13.
Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol. 2012;189(6):2689–95.
Kermani TA, Ham EK, Camilleri MJ, Warrington KJ. Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series. Semin Arthritis Rheum. 2012;42(2):213–21.
Kostine M, Truchetet M, Schaeverbeke T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology. 2019;58(Suppl 7):vii68–74.
Lenert P, Icardi M, Dahmoush L. ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review. Clin Rheumatol. 2013;32:1099–106.
Lood C, Hughes GC. Neutrophil extracellular traps as a potential source of autoantigen in cocaine-associated auto immunity. Rheumatology. 2017;56(4):638–43.
Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671–8.
Marquez J, Aguirre L, Muñoz C, Echeverri A, Restrepo M, Pinto LF. Cocaine-levamisole-induced vasculitis/vasculopathy syndrome. Curr Rheumatol Rep. 2017;19:36.
Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31(10):1955–8.
Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486–504.
Nakazawa D, Tomaru U, Suzuki A, Masuda S, Hasegawa R, Kobayashi T, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(11):3779–87.
Niro A, Recchimurzo N, Sborgia A, Guida M, Alessio G. Bilateral ischemic retinal vasculitis in metastatic cutaneous melanoma patient treated with dabrafenib and trametinib: a case report. Ocul Immunol Inflamm. 2018;26:783–5.
Ortiz-Sanjuán F, Blanco R, Hernández JL, Pina T, González-Vela MC, Fernández-Llaca H, et al. Drug-associated cutaneous vasculitis: study of 239 patients from a single referral center. J Rheumatol. 2014;41(11):2201–7.
Peuvrel L, Quereux G, Brocard A, Saint-Jean M, Freour E, Josselin N, et al. Atypical cutaneous vasculitis under lapatinib. Eur J Dermatol. 2013;23:540–1.
Pieterse E, van der Vlag J. Cracking the pathogenesis of cocaine-induced vasculitis. Rheumatology. 2017;56:503–5.
Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.
Radić M, Martinović Kaliterna D, Radić J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70:12–7.
Sainz-Gaspar L, Pita da Veiga G, Suárez-Peñaranda JM, Vázquez-Veiga H, Sánchez-Aguilar D. Leukocytoclastic vasculitis associated with rivaroxaban. Int J Dermatol. 2018;57:622–4.
Sakaue S, Sumitomo S, Kubo K, Keishi F, Yamamoto K. Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritiss. Rheumatology. 2014;53:1529–30.
Sanchez A, Lozier M, Adkinson BC, Ilaiwy A. C-ANCA vasculitis after initiation of denosumab. BMJ Case Rep. 2019;12(3):e228336.
Sehgal R, Stratman EJ, Cutlan JE. Biologic agent-associated cutaneous adverse events: a single center experience. Clin Med Res. 2018;16(1–2):41–6.
Shibata S, Asano Y, Sato S. Cutaneous polyarteritis nodosa localized to the arm receiving an infusion of abatacept. Eur J Dermatol. 2013;23:738–9.
Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012;87(8):739–45.
Sunderkötter CH, Zelger B, Chen KR, Requena L, Piette W, Carlson JA, et al. Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheumatol. 2018;70(2):171–84.
Tomelleri A, Campochiaro C, De Luca G, Cavalli G, Dagna L. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: a case series. Eur J Intern Med. 2018;57:e11–2.
Wall AE, Weaver SM, Litt JS, Rae L. Propylthiouracil-associated leukocytoclastic necrotizing cutaneous vasculitis: a case report and review of the literature. J Burn Care Res. 2017;38(3):e678–85.
Woodford RG, Becker GJ, Jain A. Leukocytoclastic vasculitis associated with use of aromatase inhibitors. Intern Med J. 2019;49(9):1162–7.
Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583–94.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Stack, J. (2022). Drug-Induced Vasculitis. In: Lee, H.Y., Creamer, D. (eds) Drug Eruptions. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-031-09388-3_14
Download citation
DOI: https://doi.org/10.1007/978-3-031-09388-3_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-09387-6
Online ISBN: 978-3-031-09388-3
eBook Packages: MedicineMedicine (R0)